View in EDS HTML Full Text PDF Full Text

Fludarabine, cyclophosphamide, and rituximab as first‐line treatment in patients with chronic lymphocytic leukemia: A long‐term analysis of the German CLL Study Group (GCLLSG) registry.

Saved in:
Bibliographic Details
Title: Fludarabine, cyclophosphamide, and rituximab as first‐line treatment in patients with chronic lymphocytic leukemia: A long‐term analysis of the German CLL Study Group (GCLLSG) registry.
Authors: Kutsch, Nadine1 (AUTHOR) nadine.kutsch@uk-koeln.de, Giza, Adam1 (AUTHOR), Robrecht, Sandra1 (AUTHOR), Stumpf, Janina1 (AUTHOR), Federhen, Anno1 (AUTHOR), Stoltefuß, Andrea2 (AUTHOR), Vehling‐Kaiser, Ursula3 (AUTHOR), Koenigsmann, Michael4 (AUTHOR), Tausch, Eugen5 (AUTHOR), Schneider, Christof5 (AUTHOR), Stilgenbauer, Stephan5 (AUTHOR), Illmer, Thomas6 (AUTHOR), Schlag, Rudolf7 (AUTHOR), Dörfel, Steffen8 (AUTHOR), Gaska, Tobias9 (AUTHOR), Kiehl, Michael10 (AUTHOR), Müller‐Hagen, Sigrun11 (AUTHOR), Moorahrend, Enno12 (AUTHOR), Linde, Hartmut13 (AUTHOR), Schlenska‐Lange, Anke14 (AUTHOR)
Source: European Journal of Haematology. Aug2024, Vol. 113 Issue 2, p235-241. 7p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:09024441
DOI:10.1111/ejh.14220